Post by Cryptobiotix

Hot off the press – SIFR predictive for in vivo metabolomics! In their latest study Nestlé Research & Development studied the impact of their low-lactose, high-GOS milk (N milk) on the adult gut microbiota. In a first step, they investigated the mechanism of action ex vivo, using our proprietary SIFR technology. Then, the researchers implemented a randomised, double-blind, controlled clinical trial to confirm the findings. https://lnkd.in/erdmc4eC   What did the results say? In the SIFR study: - 3-fold increase in median gut bifidobacteria - shift in the tryptophan metabolism, including indole-3 propionate and its precursor indole-3-lactate - increase in specific SCFAs acetate and butyrate In the clinical trial: - 3-fold increase in median gut bifidobacteria - shift in the amino acid metabolism, including indole-3 propionate - increase of 30% in the plasma SCFA levels   We are thrilled to add yet another validation that the SIFR delivers #PreclinicalDataYouCanTrust. By design, it enables you to get the clearest picture of what a product does to the gut microbiome and how this in turn affects the host. We validated the clinical predictivity of the technology, meaning that what we observe in the SIFR, will predict clinical outcomes, whether it is related to microbial composition, metabolites, or even gut barrier and immunity effects.   N milk’s appeal resides in maintaining the nutritional value of milk, while enhancing its prebiotic potential through conversion of lactose into GOS.   Thank you to the authors for this great work! Léa Siegwald, Anna Cherta Murillo, PhD, Stefan Christen, Dr Claire L Boulangé, Jason Chou, Francis Foata, Anirban Lahiry, Adrien Frézal, María Pilar Giner, Jean-Philippe Godin and Olga Sakwinska Thank you as well to cmbio, especially Morten Danielsen and Lea Giørtz Johnsen for the outstanding delivery on the ex vivo metabolomics data. #MicrobiomeResearch #Biobanking #MicrobiomeScience #GutHealth #IBDResearch #Nutrition